Biopharma & Life Sciences
Elicio Therapeutics Executive Compensation (FY24)
ELTX · Executive and director compensation, fiscal 2023 to 2024
Data as of September 7, 2026Latest filing (DEF 14A): April 9, 2025
83 figures on this page, cited to the filing that reported them. See the citations
Robert Connelly was paid $2,036,441 in total compensation as President, Chief Executive Officer, and Director for fiscal 2024, and Connelly's total was 200.2% higher than the $678,300 reported for fiscal 2023. For fiscal 2024, the company reported 3 named executive officers; the compensation disclosed runs fiscal 2023 through fiscal 2024. As an emerging growth company, the company is exempt from the advisory say-on-pay vote.
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Robert Connelly: $678,300 → $2,036,441 (200.2% higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Elicio Therapeutics' chief executive and what were they paid?
Robert Connelly was paid $2,036,441 in total compensation as President, Chief Executive Officer, and Director for fiscal 2024. Connelly's total was 200.2% higher than the $678,300 reported for fiscal 2023.
What was Elicio Therapeutics' say-on-pay result?
As an emerging growth company, the company is exempt from the advisory say-on-pay vote.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Robert Connelly President, Chief Executive Officer, and Director | ◇ | — | — | — | ◇ | — | — | ◇ |
Christopher Haqq Executive Vice President, Head of Research and Development and Chief Medical Officer | ◇ | — | — | — | ◇ | — | — | ◇ |
Peter DeMuth Chief Scientific Officer | ◇ | — | — | — | ◇ | — | — | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Robert Connelly President, Chief Executive Officer, and Director | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
Christopher Haqq Executive Vice President, Head of Research and Development and Chief Medical Officer | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
Peter DeMuth Chief Scientific Officer | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Robert Connelly | OPTION | ◇ | — | — | ◇ | — | — | — |
| Robert Connelly | OPTION | ◇ | — | — | ◇ | — | — | — |
Fiscal 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Peter DeMuth | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Christopher Haqq | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Robert Connelly | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2024
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Julian Adams, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Julian Adams | ◇ | — | ◇ | — | — | — | ◇ |
Carol Ashe | ◇ | — | ◇ | — | — | — | ◇ |
Karen J. Wilson | ◇ | — | ◇ | — | — | — | ◇ |
Allen R. Nissenson, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Robert R. Ruffolo, Jr., Ph.D., FCPP | ◇ | — | ◇ | — | — | — | ◇ |
Robert R. Ruffolo Jr., Ph.D., FCPP | ◇ | — | ◇ | — | — | — | ◇ |
Yekaterina (Katie) Chudnovsky | ◇ | — | ◇ | — | — | — | ◇ |
Jay R. Venkatesan, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Robert Connelly served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Say-on-pay history
Shareholder support for the compensation program, by year.
This company is an emerging growth company and is exempt from the advisory vote on executive compensation. There is no vote to report.
Chief executive pay ratio
As calculated and reported by the company.
This company is an emerging growth company and is not required to report a pay ratio.
What this page does not include
Everything above is a fact Elicio Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
83 figures on this page, cited to the filing that reported them.
83 cited to the filing
Documents cited
- 0001601485-25-0000622024 Summary Compensation Table · Director Compensation · Outstanding Equity Awards at 2024 Fiscal Year End · TABLE OF CONTENTS EXECUTIVE COMPENSATION
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Elicio Therapeutics executive compensation, FY2023–FY2024.” https://intel.velarion.ai/comp/ELTX (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Elicio Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}